21873158

Source:http://linkedlifedata.com/resource/pubmed/id/21873158

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0011306, umls-concept:C0027708, umls-concept:C0030956, umls-concept:C0042196, umls-concept:C0376249, umls-concept:C0439677, umls-concept:C0681842
pubmed:issue	7
pubmed:dateCreated	2011-8-29
pubmed:abstractText	The object of this study was to investigate the clinical predictive capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) vaccine therapy for patients with gynaecological cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8102988
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic, http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/HLA-A*24:02 antigen, http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens, http://linkedlifedata.com/resource/pubmed/chemical/HLA-A24 Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Subunit, http://linkedlifedata.com/resource/pubmed/chemical/WT1 Proteins
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1791-7530
pubmed:author	pubmed-author:DohiSatoshiS, pubmed-author:InoueMasakiM, pubmed-author:KyoSatoruS, pubmed-author:MyojoSubaruS, pubmed-author:OhnoSatoshiS, pubmed-author:OhtaTomihisaT, pubmed-author:OhtaYasuyukiY, pubmed-author:SugiyamaHaruoH, pubmed-author:TakanoFumihideF
pubmed:issnType	Electronic
pubmed:volume	31
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2447-52
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21873158-Adjuvants, Immunologic, pubmed-meshheading:21873158-Adult, pubmed-meshheading:21873158-Blood Cell Count, pubmed-meshheading:21873158-Cancer Vaccines, pubmed-meshheading:21873158-Combined Modality Therapy, pubmed-meshheading:21873158-Dendritic Cells, pubmed-meshheading:21873158-Female, pubmed-meshheading:21873158-Flow Cytometry, pubmed-meshheading:21873158-Genital Neoplasms, Female, pubmed-meshheading:21873158-HLA-A Antigens, pubmed-meshheading:21873158-HLA-A24 Antigen, pubmed-meshheading:21873158-Humans, pubmed-meshheading:21873158-Immunization Schedule, pubmed-meshheading:21873158-Immunologic Surveillance, pubmed-meshheading:21873158-Immunophenotyping, pubmed-meshheading:21873158-Immunotherapy, Active, pubmed-meshheading:21873158-Injections, Intradermal, pubmed-meshheading:21873158-Middle Aged, pubmed-meshheading:21873158-Peptide Fragments, pubmed-meshheading:21873158-Treatment Outcome, pubmed-meshheading:21873158-Tumor Burden, pubmed-meshheading:21873158-Vaccines, Subunit, pubmed-meshheading:21873158-WT1 Proteins
pubmed:year	2011
pubmed:articleTitle	Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
pubmed:affiliation	Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, 513, Wasedatsurumaki-cho, Shinjuku-ku, Tokyo 162-0041, Japan. satoshi.ohno55@gmail.com
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II